People

Keila Kim

linkedin.com

Keila Kim (김연주) is published in Korea Investment Partners’ current U.S. Partners directory as S. Associate. Keila focuses on life sciences investments across biopharma, next-generation biotechnology platforms, and the convergence of biology and technology. She joined Korea Investment Partners in 2022 as a biotech analyst and has since worked on both direct and GP investments in Silicon Valley. Her familiarity with both the U.S. and Korean biotech ecosystems also supports her work across cross-border investment opportunities. She evaluates companies based on scientific differentiation, commercialization potential, and scalability. She is particularly interested in companies where strong science can translate into viable products, therapies, and healthcare solutions with the potential to reach meaningful scale. Published education: B.S., Biology, University of California, Berkeley. The primary profile’s career/background list names Korea Investment Partners; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.